• PDF / 169,301 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 27 Downloads / 134 Views

DOWNLOAD

REPORT

---

1 S

Lack of efficacy: case report A 51-year-old woman exhibited lack of efficacy following treatment with adalimumab, infliximab and vedolizumab for Crohn’s disease. The woman, was diagnosed with ileal inflammatory-pattern Crohn’s disease 18 years ago. Thus, she was treated with adalimumab, infliximab and vedolizumab [routes and dosages not stated]. However, these treatments failed [durations of treatments to reaction onset not stated]. Then, subcutaneous ustekinumab was initiated as compassionate use [off-label] at 90mg at Week 0 and Week 4 and maintenance with 90mg every 8 weeks. She achieved clinical remission. However, after 8 months, she developed abdominal pain, diarrhoea and arthralgias. Thus, reinduction of IV ustekinumab 520mg with maintenance dose 90mg subcutaneously every 8 weeks. Clinical improvement was noted after 4 weeks and finally, she achieved remission at 12 weeks. Vazquez Moron JM, et al. Intravenous ustekinumab reinduction as a Crohn’s disease rescue strategy following a secondary non-response. Revista Espanola de Enfermedades 803503582 Digestivas 111: 721, No. 9, Sep 2019. Available from: URL: http://doi.org/10.17235/reed.2019.5802/2018 [Spanish; summarised from a translation]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823